Abstract

Positron Emission Tomography (PET) fosters the in vivo study of pharmacokinetics of drugs. The unrivalled sensitivity coupled with the very high specific activity with which possible new drugs can be labeled even allows pre-phase I biodistribution and structure-activity studies in man. The value of PETis illustrated by studies with s-I '-["F]-fluorocar-azolol, a recently developed radiopharmaceutical for in vivo studies of p-receptors in heart, lungs, and brain. Regulation aspects of such studies are discussed.